Which pharmaceutical company makes aprocitentan?

Aprocitentan (Aprocitentan) is an oral drug used to treat high blood pressure, with the trade name Tryvio. Developed by the Swiss biopharmaceutical company Idorsia, the drug is a dual endothelin receptor antagonist that can simultaneously block ETA and ETB receptors, thereby effectively lowering blood pressure. Aprecitentan is mainly used to treat patients with resistant hypertension who do not respond well to conventional antihypertensive drugs.

In2017, Idorsia reached a cooperation agreement with Janssen Biotech, a subsidiary of Johnson & Johnson (Janssen Biotech), to jointly develop and commercialize aprecitentan. Under the agreement, Janssen obtains global commercialization rights for the drug, while Idorsia is responsible for clinical development and is entitled to a share of future sales. However, over time, the partnership changed.

In September 2023, Idorsia announced an agreement with Janssen to regain the global development and commercialization rights of aprecitentan. According to the agreement, Idorsia will pay Janssen a consideration of up to 306 Swiss francs (approximately 343USD), depending on the marketing approval of aprecitentan in the United States and Europe. This reacquisition gives Idorsia full control over the future development and marketing of the drug.

Aprecitentan is currently approved in the United States for the treatment of high blood pressure, particularly in patients who have not responded well to other antihypertensive medications. The launch of this drug provides a new treatment option for patients with hypertension and also reflects Idorsia's research and development strength in the field of cardiovascular diseases. As the global demand for hypertension treatment increases, aprecitentan is expected to play an important role in the market in the future.

Reference materials:https://go.drugbank.com/drugs/DB15059